No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board ...

Cynthia Collins is a recognized leader with more than four decades of experience working in the pharmaceutical and biotech industry ... Chair and interim CEO of Nutcracker Therapeutics, a contract ...

This month Gov. Gavin Newsom launched a new podcast that set off political shockwaves over his exchanges with high-profile conservative guests. It left some allies, and even critics, doing a ...

Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the ...

About Nutcracker Therapeutics, Inc. Nutcracker Therapeutics, Inc. is a biotechnology CRDMO company that combines advanced engineering with high-precision biosynthesis to unlock the promise of RNA. The ...

CINCINNATI (Cincinnati Business Courier) - A growing biotech and pharmaceuticals manufacturer that announced a large investment in Greater Cincinnati a little over a year ago has unveiled new ...

Earlier this week, Novo Nordisk NVO signed an exclusive license agreement with China-based United Biotechnology for an experimental obesity drug in a deal valued at up to $2 billion. Through this ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying innovations. Chances are, the next great medical breakthrough is already in ...

Both Novo and Lilly struggled to meet demand for their obesity drugs, forcing them to spend billions of dollars to boost their manufacturing capacity. With that issue now largely resolved, Novo is ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting ...